Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial-Reference-Cited by-同舟云学术

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

Published:2016-09 Issue:9 Volume:17 Page:1283-1294
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Younes Anas,Santoro Armando,Shipp Margaret,Zinzani Pier Luigi,Timmerman John M,Ansell Stephen,Armand Philippe,Fanale Michelle,Ratanatharathorn Voravit,Kuruvilla John,Cohen Jonathon B,Collins Graham,Savage Kerry J,Trneny Marek,Kato Kazunobu,Farsaci Benedetto,Parker Susan M,Rodig Scott,Roemer Margaretha G M,Ligon Azra H,Engert Andreas

Funder

US National Institutes of Health

Publisher

Elsevier BV

Subject

Oncology

Reference22 articles.

1. WHO classification of tumours of haematopoietic and lymphoid tissues,2008

2. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial;Schmitz;Lancet,2002

3. Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation;Martinez;Ann Oncol,2013

4. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant;Arai;Leuk Lymphoma,2013

5. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma;Younes;J Clin Oncol,2012

Cited by 807 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A comprehensive review on machine learning in brain tumor classification: taxonomy, challenges, and future trends;Biomedical Signal Processing and Control;2024-12

2. Advanced stage classic Hodgkin lymphoma (cHL): biology, clinical features, therapeutic approach, and management at relapse;Leukemia & Lymphoma;2024-09-03

3. At the Cutting Edge: Novel Agents in Hodgkin Lymphoma and the Evolving Role of Radiation Therapy;International Journal of Radiation Oncology*Biology*Physics;2024-09

4. Treatment of Epstein-Barr Virus infection in immunocompromised patients;Biochemical Pharmacology;2024-07

5. Efectividad y seguridad en vida real de nivolumab en pacientes con linfoma de hodgkin clásico en recaída o refractario;Farmacia Hospitalaria;2024-06